Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Nuvectis Pharma, Inc. (NVCT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$17.76-3.84%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for NVCT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain sufficient funding to support operations into 2H 2027 | The company secured $100 million in funding to support operations through the second half of 2027. | Intact | Funding falls short of supporting operations beyond mid-2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk clinical development story, not an established earnings compounder. The thesis is in a watch state: management is advancing ciprocopan and expanding the pipeline, but recent financial performance trails its industry cohort.
The evidence gives no valuation measure or clear account of what the market assumes, so whether NVCT is cheap, fair, or expensive versus peers cannot be assessed. No priced-in fragility gates fired, but that does not resolve the uncertainty around expectations.
Near term, results may remain difficult to assess: the company is loss-making, had an August earnings miss, and has a 49% estimated chance of missing its next print. Over the multi-year view, ciprocopan has China approval, US regulatory efforts are expected in 4Q2026, and the July offering extended the stated cash runway into 1H 2029.
The thesis depends on progress toward a US marketing application for ciprocopan and on whether the Haisco pipeline expansion translates into meaningful development progress. Near-term sentiment may also be affected by company guidance, weakening jobs data, and results from Healthcare bellwethers; the evidence does not establish how these factors will resolve.
Over the next 1 to 3 years, NVCT remains a speculative, loss-making development story with a longer funded runway but meaningful execution and near-term reporting risks. The evidence is limited, so the thesis remains uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Nuvectis Pharma, Inc.'s published investment case. The stated target is EPS loss narrows or stabilizes near -$1.04 in FY26. |
| Under Pressure |
| EPS loss worsens beyond -$1.04 in FY26 |
Diluted EPS: $-1.02 per share FY2026-Q3; GAAP. Published target: EPS loss narrows or stabilizes near -$1.04 in FY26. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 2026-1.02 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Preliminary data readout from NXP900 Phase 1b study | Nuvectis Pharma aims to advance its NXP900 cancer drug with a key data readout expected in summer 2026. | Intact | Data readout is delayed beyond Q3 2026 or results are negative | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.05 → $-1.15 · observed estimates
$0.00B → $0.03B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.05 | $0 | 5 / 5 |
| 2026-07-25 | $-1.05 | $26,001,000 | 4 / 5 |
| 2026-07-26 | $-1.05 | $0 | 5 / 5 |
| 2026-07-27 | $-1.01 | $26,001,000 | 4 / 5 |
| 2026-07-28 | $-1.01 | $0 | 5 / 5 |
| 2026-07-29 | $-1.01 | $26,001,000 | 4 / 5 |
| 2026-07-30 | $-1.01 | $0 | 5 / 5 |
| 2026-07-31 | $-1.01 | $0 | 5 / 5 |
| 2026-08-01 | $-1.01 | $26,001,000 | 4 / 5 |
| 2026-08-02 | $-1.01 | $0 | 5 / 5 |
| 2026-08-03 | $-1.01 | $0 | 5 / 5 |
| 2026-08-04 | $-1.01 | $0 | 5 / 5 |
| 2026-08-05 | $-1.01 | $26,001,000 | 4 / 5 |
| 2026-08-06 | $-1.01 | $0 | 5 / 5 |
| 2026-08-07 | $-1.13 | $26,001,000 | 4 / 5 |
| 2026-08-08 | $-1.15 | $0 | 5 / 5 |
| 2026-08-09 | $-1.17 | $0 | 5 / 5 |
| 2026-08-10 | $-1.17 | $0 | 5 / 5 |
| 2026-08-12 | $-1.13 | $0 | 5 / 5 |
| 2026-08-13 | $-1.13 | $26,001,000 | 4 / 5 |
| 2026-08-14 | $-1.13 | $26,001,000 | 4 / 5 |
| 2026-08-15 | $-1.13 | $26,001,000 | 4 / 5 |
| 2026-08-16 | $-1.13 | $26,001,000 | 4 / 5 |
| 2026-08-17 | $-1.13 | $26,001,000 | 4 / 5 |
| 2026-08-18 | $-1.13 | $26,001,000 | 4 / 5 |
| 2026-08-19 | $-1.13 | $26,001,000 | 4 / 5 |
| 2026-08-20 | $-1.13 | $26,001,000 | 4 / 5 |
| 2026-08-21 | $-1.13 | $26,001,000 | 4 / 5 |
| 2026-08-22 | $-1.13 | $26,001,000 | 4 / 5 |
| 2026-08-23 | $-1.13 | $26,001,000 | 4 / 5 |
| 2026-08-24 | $-1.13 | $26,001,000 | 4 / 5 |
| 2026-08-25 | $-1.17 | $26,001,000 | 4 / 6 |
| 2026-08-26 | $-1.17 | $26,001,000 | 4 / 6 |
| 2026-08-27 | $-1.17 | $26,001,000 | 4 / 6 |
| 2026-08-28 | $-1.17 | $26,001,000 | 4 / 6 |
| 2026-08-29 | $-1.17 | $26,001,000 | 5 / 6 |
| 2026-08-30 | $-1.06 | $26,001,000 | 5 / 6 |
| 2026-08-31 | $-1.06 | $26,001,000 | 5 / 6 |
| 2026-09-01 | $-1.06 | $26,001,000 | 5 / 6 |
| 2026-09-02 | $-1.06 | $26,001,000 | 4 / 5 |
| 2026-09-03 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-04 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-05 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-06 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-07 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-08 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-09 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-10 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-11 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-12 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-13 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-14 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-15 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-16 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-17 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-18 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-19 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-20 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-21 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-22 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-23 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-24 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-25 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-26 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-27 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-28 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-29 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-09-30 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-01 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-02 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-03 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-04 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-05 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-06 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-07 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-08 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-09 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-10 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-11 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-12 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-13 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-14 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-15 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-16 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-17 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-18 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-19 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-20 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-21 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-22 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-23 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-24 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-25 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-26 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-27 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-28 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-29 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-30 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-10-31 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-11-01 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-11-02 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-11-03 | $-1.15 | $26,001,000 | 5 / 6 |
| 2026-11-04 | $-1.15 | $26,001,000 | 5 / 6 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.